TGFB1 and glioblastoma: Several anti-TGF-β antibodies, inhibitors, and antisense oligonucleotides (ASOs) against TGF-β pathway components have been evaluated in the pre-clinical and clinical trials for GBM, with limited success [18,34,35,36].